Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department()

AIMS: Ibutilide is a rapid-acting antiarrhythmic drug with worldwide use for conversion of recent-onset atrial fibrillation. Vernakalant, approved in the EU in 2010, is likewise used intravenously, with proven efficacy and safety compared with placebo and amiodarone in randomized clinical trials. Th...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Europace
Auteurs principaux: Simon, Alexander, Niederdoeckl, Jan, Skyllouriotis, Ekaterini, Schuetz, Nikola, Herkner, Harald, Weiser, Christoph, Laggner, Anton N., Domanovits, Hans, Spiel, Alexander O.
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2017
Sujets:
Clinical Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5400093/
https://ncbi.nlm.nih.gov/pubmed/28175295
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/europace/euw052
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires